Literature DB >> 17411375

Structural basis for coreceptor selectivity by the HIV type 1 V3 loop.

Timothy Cardozo1, Tetsuya Kimura, Sean Philpott, Barbara Weiser, Harold Burger, Susan Zolla-Pazner.   

Abstract

The third variable region (V3) of the HIV-1 surface glycoprotein, gp120, plays a central role in the interaction of the virus envelope with the cell surface chemokine receptors, triggering membrane fusion and virus entry into human lymphocytes and macrophages. The CXCR4 and CCR5 chemokine receptors are used by "X4-tropic" and "R5-tropic" viruses, respectively. Recently, the crown of the V3 loop was shown to bear a close structural homology to the beta2-beta3 loop in the CXC and CC chemokines, the natural ligands of CXCR4 and CCR5, respectively. This homology can serve as the foundation for 3D molecular modeling of the V3 loops from primary isolates whose coreceptor usage was experimentally defined. The modeling revealed a charged "patch" on the surface of V3 that correlates with coreceptor usage. This V3 surface patch is positively charged in X4-tropic viruses and negatively charged or neutral in R5-tropic viruses, and is formed by two amino acids, at position 11 and at position 24 or 25; amino acids 11 and 24 or 11 and 25 contact each other in 3D space. Residues at positions 11 and 25 were known previously to influence coreceptor usage, and the charge of the residues at these two positions is often used to predict viral tropism. However, we found that the predictive value of using the charge of residues 11, 24, and 25 to identify X4 or R5 tropism was improved over using only the charge of residues 11 and 25. Thus, the data suggest a new " 11/24/25 rule" : a positively charged amino acid at position 11, 24, or 25 defines X4; otherwise R5. This rule gave an overall predictive value of 94% for 217 viruses whose tropism had been determined experimentally as either X4 or R5. The results have additional implications for the design of HIV therapeutics, vaccines, and strategies for monitoring disease progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17411375     DOI: 10.1089/aid.2006.0130

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  95 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

2.  Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.

Authors:  Silvia Baroncelli; Clementina Maria Galluzzo; Liliana Elena Weimer; Maria Franca Pirillo; Anna Volpe; Alessandra Mercuri; Albertina Cavalli; Vincenzo Fragola; Laura Monno; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Raffaella Bucciardini; Marco Floridia
Journal:  J Antimicrob Chemother       Date:  2012-02-23       Impact factor: 5.790

3.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

4.  A novel denaturing heteroduplex tracking assay for genotypic prediction of HIV-1 tropism.

Authors:  Binshan Shi; Barbara Weiser; Linda M Styer; Kimdar Kemal; Cheryl Brunner; Kathryn Anastos; Harold Burger
Journal:  J Virol Methods       Date:  2012-06-21       Impact factor: 2.014

5.  Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Authors:  Wei Huang; Arne Frantzell; Jonathan Toma; Signe Fransen; Jeannette M Whitcomb; Eric Stawiski; Christos J Petropoulos
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.616

6.  Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Authors:  Yosuke Maeda; Taichiro Takemura; Takayuki Chikata; Takeo Kuwata; Hiromi Terasawa; Riito Fujimoto; Nozomi Kuse; Tomohiro Akahoshi; Hayato Murakoshi; Giang Van Tran; Yu Zhang; Chau Ha Pham; Anh Hong Quynh Pham; Kazuaki Monde; Tomohiro Sawa; Shuzo Matsushita; Trung Vu Nguyen; Kinh Van Nguyen; Futoshi Hasebe; Tetsu Yamashiro; Masafumi Takiguchi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

7.  Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Authors:  Richard M Gibson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

8.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

9.  Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.

Authors:  Seble Kassaye; Elizabeth Johnston; Bryan McColgan; Rami Kantor; Lynn Zijenah; David Katzenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

10.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.